Uric acid levels, left ventricular mass and geometry in newly diagnosed, never treated hypertension

Journal of Human Hypertension

Volumn 25, Issue 5, 2011, Pages 340-342

  Xaplanteris, P ^a   Vlachopoulos, C ^a   Vyssoulis, G ^a   Terentes Printzios, D ^a   Alexopoulos, N ^a   Lazaros, G ^a   Stefanadis, C ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE MARKER; FEMALE; GEOMETRY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; URIC ACID BLOOD LEVEL;

BLOOD FLOW VELOCITY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PULSATILE FLOW; URIC ACID;

EID: 79954650565     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.120     Document Type: Article

References (12)

1. Vlachopoulos C, Xaplanteris P, Vyssoulis G, Bratsas A, Baou K, Tzamou V et al. Association of serum uric acid level with aortic stiffness and arterial wave reflec-tions in newly diagnosed, never-treated hypertension. Am J Hypertens 2011; 24(1): 33-39.
2. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assess-ment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57(6): 450-458. (Pubitemid 16119719)
3. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45(1): 18-20. (Pubitemid 40066407)
4. Mitsuhashi H, Yatsuya H, Matsushita K, Zhang H, Otsuka R, Muramatsu T et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J 2009; 73(4): 667-672.
5. Kuo CF, Yu KH, Luo SF, Ko YS, Wen MS, Lin YS et al. Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. Rheumatology (Oxford) 2010; 49(6): 1189-1196.
6. Kurata A, Shigematsu Y, Higaki J. Sex-related differ-ences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients. Hypertens Res 2005; 28(2): 133-139. (Pubitemid 40663064)
7. Ichihara S, Senbonmatsu T, Price Jr E, Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced Hypertension. Circulation 2001; 104(3): 346-351. (Pubitemid 32666959)
8. Shi Y. Caught red-handed: uric acid is an agent of inflammation. J Clin Invest 2010; 120(6): 1809-1811.
9. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28(6): 1234-1242.
10. Vlachopoulos C, Aznaouridis K, Stefanadis C. Pre-diction of cardiovascular events and all-cause mortal-ity with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55(13): 1318-1327.
11. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114(23): 2508-2516. (Pubitemid 44901524)
12. Rayner BL, Trinder YA, Baines D, Isaacs S, Opie LH. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hyper-tension and hyperuricemia associated with diuretics. Am J Hypertens 2006; 19(2): 208-213. (Pubitemid 43350176)